RTX A/S logo

RTX A/S (RTX)

Market Open
14 Aug, 15:00
XCSE XCSE
kr
93. 20
+0.2
+0.2151%
kr
- Market Cap
30.5 P/E Ratio
0.6% Div Yield
1,842 Volume
0 Eps
kr 93
Previous Close
Add Transaction
Day Range
93.2 95
Year Range
77.2 120
Want to track RTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

RTX trading today higher at kr93.2, an increase of 0.2151% from yesterday's close, completing a monthly decrease of -1.4799% or -kr1.4. Over the past 12 months, RTX stock lost -13.3023%.
RTX is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XDUS (EUR).

RTX Chart

RTX A/S (RTX) FAQ

What is the stock price today?

The current price is kr93.20.

On which exchange is it traded?

RTX A/S is listed on XCSE.

What is its stock symbol?

The ticker symbol is RTX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.6%.

What is its market cap?

As of today, no market cap data is available.

Has RTX A/S ever had a stock split?

No, there has never been a stock split.

RTX A/S Profile

Biotechnology Industry
Healthcare Sector
Mr. Dao Xing Fu CEO
XCSE Exchange
DK0010267129 ISIN
CN Country
4,858 Employees
- Last Dividend
- Last Split
18 May 1998 IPO Date

Overview

Beijing Tiantan Biological Products Co., Ltd. is a prominent player in the biopharmaceutical industry, primarily focused on the research and development, manufacture, sale, and consulting of blood products. Founded in 1919 and with its headquarters established in Beijing, China, this company has carved a niche for itself in the Chinese biopharmaceutical sector. As a subsidiary of China National Biotec Group Company Limited, Beijing Tiantan Biological Products operates under a considerable banner, contributing significant advancements and innovations in the field of biotechnology and pharmaceuticals, with a strong emphasis on products derived from human blood.

Products and Services

The company's portfolio encompasses a diverse range of blood-related products, tailored to meet a variety of medical needs. Their product lineup includes:

  • Human Albumin: A vital protein used in the treatment of shocks, burns, and low blood protein levels. It plays a crucial role in maintaining blood volume and pressure.
  • Intravenous Human Immunoglobulin: A therapy used for a range of immune deficiencies and autoimmune and inflammatory diseases, providing essential antibodies to patients with deficient or malfunctioning immune systems.
  • Tetanus Human Immunoglobulin: Specifically used for the prevention and treatment of tetanus, offering immediate immunity through the provision of tetanus antibodies.
  • Rabies Patient Immunoglobulin: Used as post-exposure prophylaxis against rabies infections, providing immediate but temporary antibodies to fight the virus following exposure.
  • Hepatitis B Human Immunoglobulin: Administered to prevent hepatitis B infection in individuals exposed to the virus, as well as in other specific medical situations like the newborns of mothers who are hepatitis B surface antigen positive.
  • Freeze-dried Intravenous Hepatitis B Human Immunoglobulin: A specialized formulation of hepatitis B immunoglobulin, designed for intravenous administration, offering convenience and improved stability.
  • Human Prothrombin Complex: This product is crucial for patients with clotting disorders, providing a concentrate of clotting factors to manage and prevent bleeding episodes.

Contact Information

Address: No.B2 Shuangqiao Road, Beijing, China, 100024
Phone: 86 10 6543 4018